Sinopharm sets price range for $1.13 billion IPO

By Anette Jönsson | 4 September 2009
Keywords: ipo | healthcare | pharmaceuticals | sinopharm | cicc | morgan stanley | ubs
Subscriber Content Preview.
Subscribe now for full access or call us now on +852 2122 5222.

The Chinese distributor of pharmaceutical products will be the first company to take orders for a Hong Kong listing after the summer and has set the price range at HK12.25 to HK$16 per share.

Sinopharm, the largest distributor of pharmaceutical products in China, will be the first company to start accepting orders for a Hong Kong initial public offering when it kicks off its roadshow today. It is getting a head start on the five companies that are currently engaged in investor education and several others that are expected to follow in the weeks ahead.

The state-owned company will seek to raise between HK$6.68 billion and HK$8.73 billion ($862 million to $1.13 billion) after sources said it has set the price range at HK$12.25 to HK$16 per share. This will make it ...

To continue reading this article, subscribe now or call us now on +852 2122 5222.
You need a subscription to view this article
Articles older than 48 hours are available to subscribers only.

Log in below or buy a subscription to enjoy unlimited access to FinanceAsia.com's quickly growing 13,000 article database.
 
 
 
Polls
In which market is it hardest to hire finance professionals?


   |   View results
Hong Kong
  14%
 
Shanghai
  64%
 
Singapore
  22%
TOTAL VOTES: 95

 
Magazine
FinanceAsia Magazine
FinanceAsia
March 2010